Vigonvita Life Sciences Co., Ltd.

Vigonvita Life Sciences Co., Ltd., a biopharmaceutical company, engages in the discovery, development, and commercialization of small molecule drugs for neuropsychiatry, reproductive health, and viral infection therapeutic areas. Its products include LV232, a first-in-class dual-target 5-HTT/5-HT modulators, which is in Phase II of clinical trial for the treatment of depressive disorder; and TPN171, a type-5 phosphodiesterase inhibitor completed Phase III clinical trial for the treatment of erectile dysfunction. The company also develops VV116, a RNA-dependent RNA polymerase inhibitor completed a Phase II clinical trial for the treatment of respiratory syncytial virus infection, as well as COVID-19 infections; TPN102, a novel antiepileptic drug, which is in Phase I clinical trial for the treatment of epilepsy; VV119, a multi-target serotonin-dopamine activity modulator, which is in Phase I clinical trial for the treatment of psychiatric disorders and schizophrenia; VV261, a novel nucleoside prodrug, which is in Phase I clinical trial for chikungunya, coronaviruses, influenza, and arena virus. In addition, it develops VV913, a novel investigational drug candidate for premature ejaculation; VV147 for the treatment of major depressive disorder; and VV207 for the treatment of adenovirus infection. The company was incorporated in 2013 and is headquartered in Suzhou, China.

行业

Drug Manufacturers - General

部门

Healthcare

总部

CN

首席执行官

Guanghui Tian

上市以来

2025年11月6日

雇员

315